Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers

Aurobindo Pharma Q4FY21 consolidated net profit at Rs. 801.58 Cr

The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021

Aurobindo Pharma to acquire 26% ownerships solar power companies

The company will be holding 26% of the share capital in each of the solar power generating companies.

Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities

Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.

APL Healthcare’s Unit-IV classified as VAI by the USFDA

This inspection is now closed

Eugia Pharma launches Pomalidomide capsules in US market

Eugia Pharma receives USFDA Approval for Everolimus tablets

Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules

CuraTeQ Biologics and BioFactura USA to terminate agreement mutually

Apitoria Pharma receives 3 observations from USFDA for Unit-V

The company will respond to the US FDA within the stipulated timelines

CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar

Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints